Fermenta Biotech reports Environment loss of Rs 4.46 crore

Fermenta Biotech Limited identified Environment as a separate reportable segment in the quarter ended September 30, 2026 after it met an Indian Accounting Standard 108 threshold, and the business reported a Rs 4.46 crore segment loss on Rs 16.71 crore of revenue for the half year ended that date.

Why did Fermenta Biotech disclose Environment as a separate segment?

Fermenta Biotech disclosed Environment separately because the business met the quantitative threshold prescribed under Indian Accounting Standard 108, Operating Segments, during the September 30, 2026 quarter. The company made the disclosure in unaudited consolidated results that its board approved on November 5, 2026. The filing does not identify the individual threshold test that caused the business to become reportable.

The segment note now separates Environment from bulk drugs/chemicals, property and unallocated activities. For the half year ended September 30, 2026, Environment generated Rs 16.71 crore of revenue, compared with Rs 239.70 crore for bulk drugs/chemicals and Rs 3.98 crore for property. Consolidated total income was Rs 261.95 crore, down from Rs 280.69 crore in the corresponding half year ended September 30, 2025.

Separate reporting also shows the relative contribution of each business to segment results. Bulk drugs/chemicals delivered a Rs 38.03 crore segment result in the September 2026 half year, while Environment recorded a loss and property contributed Rs 0.08 crore. Fermenta Biotech's consolidated profit before exceptional items and tax fell to Rs 28.94 crore from Rs 52.17 crore a year earlier.

How did Fermenta Biotech's Environment business perform?

Fermenta Biotech's Environment revenue increased to Rs 16.71 crore in the half year ended September 30, 2026 from Rs 15.27 crore in the corresponding 2025 period, but its segment loss widened to Rs 4.46 crore from Rs 3.44 crore. Revenue therefore increased by Rs 1.44 crore, while the loss increased by Rs 1.02 crore over the two six-month periods.

In the September 2026 quarter, Environment revenue was Rs 10.72 crore, compared with Rs 5.99 crore in the June 2026 quarter and Rs 8.60 crore in the September 2025 quarter. Its quarterly loss narrowed to Rs 1.76 crore from Rs 2.71 crore in June, but remained above the Rs 1.13 crore loss reported a year earlier. The quarterly figures show higher revenue and a smaller loss sequentially.

Environment's Rs 4.46 crore first-half loss contrasted with the Rs 38.03 crore result in bulk drugs/chemicals and Rs 0.08 crore in property. Property's result fell from Rs 1.79 crore in the previous year's first half. The segment data show that the bulk drugs/chemicals business remained the principal reported source of segment profit while Environment remained loss-making.

What changed in Fermenta Biotech's Environment assets and liabilities?

Fermenta Biotech reported Environment segment assets of Rs 25.29 crore at September 30, 2026, compared with Rs 24.25 crore at March 31, 2026 and Rs 22.74 crore at September 30, 2025. Assets increased by Rs 1.04 crore during the first six months of the financial year and by Rs 2.55 crore from the year-earlier reporting date.

Environment segment liabilities stood at Rs 9.93 crore at September 30, 2026, up from Rs 8.54 crore at March 31, 2026 and Rs 4.16 crore a year earlier. The six-month increase was Rs 1.39 crore, while the year-on-year increase was Rs 5.77 crore. The filing presents these as segment balances and does not provide a line-by-line explanation for the movements.

The Environment business had a smaller asset base than bulk drugs/chemicals, whose segment assets were Rs 553.58 crore at September 30, 2026. Fermenta Biotech reported total segment assets of Rs 695.66 crore at that date, compared with Rs 647.94 crore at March 31, 2026. Environment's liabilities rose faster than its assets during the six-month period, based on the disclosed segment figures.

The consolidated balance sheet recorded total equity of Rs 412.09 crore and current liabilities of Rs 250.39 crore at September 30, 2026. Unallocated activities accounted for Rs 110.33 crore of segment liabilities, while Environment accounted for Rs 9.93 crore. These allocations mean the segment figures are not a standalone statutory balance sheet for the Environment business.

What funding and employee-option actions did Fermenta Biotech disclose?

Fermenta Biotech subsidiary Fermenta Environment Solutions Private Limited issued 717,949 new equity shares through a private placement during the September 2026 quarter at Rs 12 per share. Under the shareholder agreement, the subsidiary received 25% of the subscription amount, or Rs 21.53 lakh. The announcement does not identify the subscriber or state when the remaining subscription amount will be received.

Fermenta Environment Solutions Private Limited also granted 1,578,945 employee stock options in the quarter under the Fermenta Environment Solutions Private Limited Employee Stock Option Plan 2026. Each option has an exercise price of Rs 10 and can be exercised into one equity share of Rs 10, subject to vesting conditions. The filing does not give the vesting schedule, expiry period or employee categories covered by the grants.

At group level, Fermenta Biotech recorded Rs 2.74 crore of employee share-based payments in the half year ended September 30, 2026, compared with Rs 1.43 crore in the corresponding 2025 period. The filing establishes that the private placement and option grant occurred in the same quarter as the separate segment designation, but does not connect either action to a specific project or profitability target.

The announcement also does not disclose a management plan for addressing the Environment segment's Rs 4.46 crore first-half loss. It provides no revenue target, capacity plan or expected timing for improved profitability. The disclosed facts are limited to the segment's financial data, the share issue and the employee-option award.

Conclusion

Fermenta Biotech's new disclosure gives a separate view of an Environment business whose first-half revenue increased from Rs 15.27 crore to Rs 16.71 crore, while its loss increased from Rs 3.44 crore to Rs 4.46 crore. The segment's assets reached Rs 25.29 crore and liabilities reached Rs 9.93 crore by September 30, 2026, alongside continued profitability in bulk drugs/chemicals.

The next disclosures may clarify whether the September-quarter loss of Rs 1.76 crore, lower than June's Rs 2.71 crore, is sustained. Readers can also watch for the outstanding portion of the Rs 12-per-share private-placement subscription and for vesting details on the 1,578,945 employee options, both of which remain undisclosed in the filing.